SCHEMBL4919967

SCHEMBL4919967

CCc1cc(-c2ccc(C#N)cc2)c(C)[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.47
CYP11B2 P19099 3/20 0.44
KDM4E B2RXH2 2/20 0.41
HPGD P15428 2/20 0.41
ALDH1A1 P00352 2/20 0.41
GALR3 O60755 1/20 0.41
GAA P10253 1/20 0.41
TSHR P16473 2/20 0.39
PDE3B Q13370 2/20 0.39
PDE3A Q14432 2/20 0.39
PDE5A O76074 1/20 0.39
LMNA P02545 1/20 0.39
PTGS1 P23219 1/20 0.39
PDE4A P27815 1/20 0.39
CYP2C19 P33261 1/20 0.39
BLM P54132 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
KDM1A O60341 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4915366 0.88 CYP11B2 (0.42) CYP2A6CYP11B2KDM4EHPGDALDH1A1
SCHEMBL4921058 0.80 ALDH1A1 (0.45) CYP2A6CYP11B2KDM4EHPGDALDH1A1
SCHEMBL5361548 0.78 KDM4E (0.44) CYP2A6CYP11B2KDM4EHPGDALDH1A1
SCHEMBL14154900 0.78 PDE3B (0.40) KDM4EHPGDALDH1A1PDE3BPDE3A
SCHEMBL4919741 0.74 PDE3B (0.46) CYP2A6CYP11B2HPGDALDH1A1TSHR
SCHEMBL5369669 0.73 KIF11 (0.46) CYP2A6CYP11B2KDM4EHPGDALDH1A1
SCHEMBL8210361 0.73 KDM4E (0.75) CYP11B2KDM4EHPGDALDH1A1GALR3
SCHEMBL5355750 0.73 ALDH1A1 (0.43) CYP2A6CYP11B2KDM4EHPGDALDH1A1
SCHEMBL4910777 0.72 KDM1A (0.41) CYP11B2KDM4EHPGDALDH1A1GALR3
SCHEMBL13061701 0.71 CYP2A6 (0.47) CYP2A6CYP11B2TSHRHSD17B10PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176906-A1 Substituted Pyrrole Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 US disclosed
US-20080176906-A1 Substituted Pyrrole Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 US disclosed
WO-2007145349-A2 SUBSTITUTED PYRROLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-12-21 WO disclosed
WO-2007145349-A2 SUBSTITUTED PYRROLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-12-21 WO disclosed
EP-1824841-A1 SUBSTITUTED PYRROLE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2007-08-29 EP disclosed
WO-2006064944-A1 SUBSTITUTED PYRROLE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176906-A1 Substituted Pyrrole Derivative AR, NR5A1, MC2R CYP2A6 104/4885CYP11B2 81/4885KDM4E 373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.